Search
English
中文
About Us
At a Glance
History and Milestones
Global Recognition
Management Team
Research & Development
Oncology
Autoimmune Diseases
Facility and Capacity
Products
Pipeline Overview
HMPL-004
HMPL-011
Sulfatinib
Fruquintinib
HMPL-813
Collaborations
Collaboration Overview
Existing Partnerships
Media
Key Facts
Press Releases
Featured Articles
Careers
Contacts
About Us
Hutchison Medi Pharma is an entrepreneurial, China-based, global quality drug development company with a rich pipeline, first class R&D leadership and a proven track record.
Product Pipeline
With a rich and unique pipeline in oncology and autoimmune disease, the Company has compounds in pre-clinical, phase I, phase II and phase III development in the US, Europe, Australia and China.
sohbet
sohbet
escort istanbul
ankara escort
dizi izle
Latest News
04/24/2013
Nutrition Science Partners announces initiation and treatment of the first Ulcerative Colitis patient in the global NATRUL Phase III trial for the novel botanical oral drug HMPL-004
04/08/2013
Presentations of Fruquintinib Phase I Clinical Data and Volitinib Preclinical Data at the 2013 AACR Annual Meeting
Recent Awards
